Injectables · Neurotoxins · daxibotulinumtoxinA-lan
DAXXIFY is the first and only FDA-approved neuromodulator formulated with Peptide Exchange Technology (PEP). In pivotal clinical trials, median duration reached approximately six months — notably longer than conventional botulinum toxin treatments — while onset remained similar, typically within three to seven days.
A consultation confirms candidacy and dosing. DAXXIFY is currently FDA-approved for glabellar lines; off-label areas may be discussed with your Aurevia injector based on experience and your goals.
A refined lunch-hour procedure. After reviewing your anatomy and goals, your injector cleans the glabellar area and administers DAXXIFY with an ultra-fine needle. Most sessions take 15–20 minutes. No anesthesia is required — you can return to normal activities immediately, following standard post-neurotoxin guidelines.
Similar timing to other toxins. Softening typically begins within three to seven days, with full effect by two weeks. Avoid rubbing the treated area, strenuous exercise for 24 hours, and lying flat for several hours after injection. These simple steps help the product settle precisely where intended.
Designed to last longer. In the SAKURA 1 and SAKURA 2 Phase 3 trials, DAXXIFY demonstrated a median duration of approximately six months for glabellar lines — longer than the three-to-four-month average of conventional neuromodulators. Your metabolism, dose, and muscle activity influence individual longevity.
Still requires follow-up. Even with extended duration, DAXXIFY is not permanent. When movement returns, a maintenance visit preserves smoothness. Many patients schedule two treatments per year rather than three or four — a meaningful difference for busy Irvine schedules.
Conventional botulinum toxins rely on human or animal-derived proteins to stabilize the active molecule. DAXXIFY replaces those stabilizers with a novel peptide — creating a uniquely formulated neuromodulator with extended clinical duration.
DAXXIFY contains daxibotulinumtoxinA-lan — a type A botulinum toxin that temporarily relaxes targeted muscles. By blocking nerve signals, it reduces the repetitive contractions that etch frown lines between the brows.
Peptide Exchange Technology (PEP) uses a synthetic peptide to stabilize the toxin instead of human serum albumin or other animal-derived proteins found in many existing neuromodulators. This innovative formulation is proprietary to DAXXIFY.
The PEP formulation is engineered to enhance stability and prolong the toxin's activity at the neuromuscular junction. Clinical trials reflected this design: median glabellar line improvement lasted approximately six months — a meaningful extension over conventional options.
The FDA approved DAXXIFY in September 2022 for the temporary improvement of moderate to severe glabellar lines in adults. Aurevia injectors apply this technology with the same precision and artistry as every neurotoxin we offer.
Traditional neuromodulators wrap the active toxin in complexing proteins to keep it stable before injection. DAXXIFY's peptide-based approach offers a distinct molecular profile — one designed from the ground up for durability at the injection site.
In head-to-head clinical studies, DAXXIFY's median duration exceeded that of conventional botulinum toxin A products for glabellar lines, without sacrificing the natural-looking softening patients expect. Onset remained comparable — typically three to seven days — so you do not trade speed for longevity.
At Aurevia in Irvine, we help you decide whether DAXXIFY's extended wear fits your lifestyle, anatomy, and aesthetic goals — or whether another neurotoxin in our portfolio is the better match.
Extended duration is especially appealing for certain patient profiles. If any of these sound like you, DAXXIFY may be worth exploring at your Aurevia consultation.
Fewer appointments per year means less time away from work, travel, and family — without compromising a polished appearance.
If Botox, Dysport, or Xeomin wears off quickly for you, DAXXIFY's extended median duration may offer noticeably longer smoothness between visits.
Patients who want reliable frown line correction with roughly two sessions annually rather than three or four maintenance cycles.
Those interested in a neuromodulator stabilized with synthetic peptides rather than human or animal-derived complexing proteins.
New to injectables? DAXXIFY's longer wear window can make your first experience less daunting — one treatment, months of benefit.
Ideal for moderate to severe frown lines between the eyebrows — the indication for which DAXXIFY received FDA approval in September 2022.
Longer-lasting results only matter when they look natural. At Aurevia, our Irvine injectors pair DAXXIFY's peptide exchange technology with precise placement and conservative dosing — so you enjoy extended smoothness without sacrificing expression.Aurevia Skincare · Irvine
In pivotal Phase 3 clinical trials (SAKURA 1 and SAKURA 2), DAXXIFY demonstrated a median duration of approximately six months for glabellar line improvement — longer than the three-to-four-month average of conventional botulinum toxins. Individual results vary based on metabolism, muscle strength, dose, and treatment area. When effects begin to fade, maintenance treatments restore smoothness.
Both are type A botulinum toxins, but they differ in formulation and duration. Botox (onabotulinumtoxinA) uses complexing proteins for stabilization and typically lasts three to four months. DAXXIFY (daxibotulinumtoxinA-lan) uses Peptide Exchange Technology (PEP) — a synthetic peptide stabilizer instead of human or animal-derived proteins — and showed a median duration of approximately six months in clinical trials. Unit measurements also differ; only an experienced injector should calculate your dose.
As with all botulinum toxin products, side effects are possible. The most commonly reported in clinical trials included headache, eyelid drooping (ptosis), and injection-site reactions such as pain, swelling, or bruising. Less common effects may include facial asymmetry or brow elevation. Serious but rare risks include spread of toxin effect and difficulty swallowing or breathing. Disclose your full medical history — including neuromuscular conditions — before treatment.
Onset is similar to other neuromodulators: most patients notice softening within three to seven days, with full effect typically visible by two weeks. DAXXIFY's extended duration does not mean slower onset — you get comparable speed with longer-lasting glabellar line improvement.
Yes. DAXXIFY temporarily relaxes treated muscles — it is not permanent. Even with a median duration of approximately six months, you will eventually need a follow-up visit to maintain results. Many patients find that two treatments per year suffice, compared with three or four sessions with conventional toxins. Your Aurevia injector will recommend a maintenance schedule based on how your results evolve.
Aurevia is the premier Irvine skincare clinic for aesthetic and beauty treatments. Discover whether DAXXIFY's extended-duration peptide technology is right for you with a complimentary consultation from our highly trained injectors.